Mason Henderson, a 21-year-old from southeastern Texas, was diagnosed with a rare and aggressive form of brain cancer known as diffuse hemispheric glioma (H3 G34-mutant) in 2024. This type of cancer is particularly difficult to treat because it spreads quickly and often affects the spinal fluid, a condition called leptomeningeal disease. This condition is typically fatal within a few months, making Henderson’s case especially challenging. His initial treatment included chemotherapy, which did not halt the progression of the tumor. Later, he participated in a clinical trial in New York City, but that also failed to provide a solution. Henderson’s doctors, including Jacob Mandel from Baylor College of Medicine and Jessica Schulte from NYU Langone Health, decided to try Lynparza, a drug developed by Merck and AstraZeneca. Lynparza, approved by the FDA in 2014 for ovarian cancer, works by disrupting the ability of cancer cells to repair themselves and multiply. The doctors believed the drug could target the specific genetic flaw in Henderson’s tumor. However, his insurance company refused to cover Lynparza, citing a lack of established guidelines for treating rare cancers. Henderson’s mother, Tabitha Lowe, explained that patients with rare conditions often face discrimination from insurers due to the absence of standardized treatment protocols. Henderson’s family sought coverage through Jefferson County, where his stepfather works for the sheriff’s office. The county also denied coverage and referred the case to an independent medical reviewer, who recommended a different drug that Henderson’s doctors did not support. AstraZeneca initially declined a request for a drug donation, but after months of advocacy by Henderson’s family, the company’s patient assistance program provided a bottle of Lynparza. Henderson began treatment in March 2024, but by mid-April, he was unable to walk and had difficulty speaking. He passed away on May 4, 2024, after nearly two months on the drug. Henderson’s story underscores the challenges faced by patients with rare cancers, which often lack targeted and FDA-approved treatments. Insurers typically rely on FDA approvals and expert guidelines, which are scarce for rare conditions. While genomic testing can identify potential treatment options, large clinical trials for these cancers are rare. Scientists and oncologists are increasingly focusing on more precise drug targets based on the molecular makeup of tumors. The FDA has approved some “tissue-agnostic” drugs that treat specific genetic mutations regardless of where the cancer originates, but such treatments are still limited. Insurers must keep pace with advancements in genomic science to better support patients. In honor of Mason, his family has established a college scholarship in his name for graduates of their local high school. An online fundraising campaign and a bass fishing tournament have raised nearly $24,000 by September. Henderson’s mother expressed deep regret over the time spent fighting the healthcare system instead of being with her son. She called for faster access to treatment and better support for those with rare cancers, emphasizing the need for the medical and insurance systems to adapt to the growing understanding of cancer’s genetic complexity.